Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.73 [0.59, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.92 [0.77, 1.10] | | < 1 | | 0% | 1 study (1/-) | 82.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 1.70 [1.11, 2.61] | | > 1 | | 0% | 1 study (1/-) | 99.2 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.31 [0.20, 0.48] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.42 [0.29, 0.59] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 0.32 [0.19, 0.55] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
STRAE (grade 3-4) | 0.25 [0.14, 0.46] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.10 [0.06, 0.16] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Acute kidney injury TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.13 [0.02, 1.07] | | < 1 | | 0% | 1 study (1/-) | 97.1 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.15 [0.02, 1.28] | | < 1 | | 0% | 1 study (1/-) | 95.8 % | NA | not evaluable | | non important | - |
Blood creatinine increased TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.23 [0.01, 5.17] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.15 [0.01, 3.09] | | < 1 | | 0% | 1 study (1/-) | 88.6 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.62 [0.10, 3.74] | | < 1 | | 0% | 1 study (1/-) | 69.8 % | NA | not evaluable | | non important | - |
Dysgeusia TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Eczema TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Erythema TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.21 [0.06, 0.74] | | < 1 | | 0% | 1 study (1/-) | 99.2 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.27] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Hypersensitivity TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 0.47 [0.02, 13.95] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Increased lacrimation (TRAE grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.47 [0.02, 13.95] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.02 [0.00, 0.32] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.09 [0.00, 1.69] | | < 1 | | 0% | 1 study (1/-) | 94.4 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.93 [0.13, 6.67] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.00 [0.00, 0.08] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.15 [0.01, 3.09] | | < 1 | | 0% | 1 study (1/-) | 88.6 % | NA | not evaluable | | non important | - |
Peripheral oedema TRAE (grade 3-4) | 0.47 [0.02, 13.95] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 2.82 [0.29, 27.28] | | < 1 | | 0% | 1 study (1/-) | 18.7 % | NA | not evaluable | | non important | - |
Pruritic rash TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Pruritus generalised TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Skin exfoliation TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.23 [0.01, 5.17] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Urticaria TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.15 [0.01, 3.09] | | < 1 | | 0% | 1 study (1/-) | 88.6 % | NA | not evaluable | | non important | - |
Alopecia AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.38 [0.13, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.4 % | NA | not evaluable | | non important | - |
Arthralgia AE (grade 3-4) | 0.93 [0.13, 6.67] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.84 [0.35, 2.02] | | < 1 | | 0% | 1 study (1/-) | 64.9 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 2.36 [0.45, 12.26] | | < 1 | | 0% | 1 study (1/-) | 15.5 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.93 [0.13, 6.67] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 1.17 [0.31, 4.40] | | < 1 | | 0% | 1 study (1/-) | 40.8 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.93 [0.19, 4.66] | | < 1 | | 0% | 1 study (1/-) | 53.3 % | NA | not evaluable | | non important | - |
Dizziness AE (grade 3-4) | 0.93 [0.06, 15.00] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
Dry skin AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dysgeusia AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 1.32 [0.58, 3.03] | | < 1 | | 0% | 1 study (1/-) | 25.4 % | NA | not evaluable | | non important | - |
Erythema AE (grade 3-4) | 0.47 [0.02, 13.95] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.45 [0.20, 1.02] | | < 1 | | 0% | 1 study (1/-) | 97.2 % | NA | not evaluable | | non important | - |
Febrile neutropenia AE (grade 3-4) | 0.01 [0.00, 0.24] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 3.75 [0.17, 83.63] | | < 1 | | 0% | 1 study (1/-) | 20.5 % | NA | not evaluable | | non important | - |
Hypothyroidism AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 0.93 [0.06, 15.00] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
Lacrimation increased AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Leucopenia AE (grade 3-4) | 0.02 [0.00, 0.31] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Mucosal inflammation AE (grade 3-4) | 0.18 [0.02, 1.58] | | < 1 | | 0% | 1 study (1/-) | 93.7 % | NA | not evaluable | | non important | - |
Myalgia AE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 2.36 [0.45, 12.26] | | < 1 | | 0% | 1 study (1/-) | 15.5 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.01 [0.00, 0.07] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Oropharyngeal pain AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Paraesthesia AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Peripheral neuropathy AE (grade 3-4) | 0.15 [0.01, 3.09] | | < 1 | | 0% | 1 study (1/-) | 88.6 % | NA | not evaluable | | non important | - |
Peripheral oedema AE (grade 3-4) | 0.93 [0.13, 6.67] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
Pneumonia AE (grade 3-4) | 0.65 [0.29, 1.50] | | < 1 | | 0% | 1 study (1/-) | 84.1 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Stomatitis AE (grade 3-4) | 0.47 [0.04, 5.16] | | < 1 | | 0% | 1 study (1/-) | 73.2 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 1.87 [0.06, 55.99] | | < 1 | | 0% | 1 study (1/-) | 36.1 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |